10-Q: Delcath Systems Reports Strong Revenue Growth in Q3 2024 Driven by HEPZATO Kit Sales

Delcath Systems saw a significant increase in revenue in the third quarter of 2024, primarily due to the commercial launch of its HEPZATO Kit in the U.S.

Summary

• Delcath Systems reported a substantial increase in product revenue for the three and nine months ended September 30, 2024, compared to the same periods in 2023.
• The revenue growth is primarily attributed to the commercial launch of the HEPZATO Kit in the U.S. during the first quarter of 2024 and increased demand for CHEMOSAT in Europe.
• Total revenue for the three months ended September 30, 2024, was $11.2 million, compared to $0.4 million in the same period of 2023.
• Total revenue for the nine months ended September 30, 2024, was $22.1 million, compared to $1.5 million in the same period of 2023.
• The company experienced an operating loss of $1.3 million for the three months ended September 30, 2024, and $15.4 million for the nine months ended September 30, 2024.
• Delcath reported a net income of $1.9 million for the three months ended September 30, 2024, compared to a net loss of $20.3 million for the same period in 2023.
• The company reported a net loss of $23.0 million for the nine months ended September 30, 2024, compared to a net loss of $36.5 million for the same period in 2023.
• As of September 30, 2024, Delcath had cash and cash equivalents of $8.3 million and short-term investments of $5.7 million.
• The company used $17.7 million in operating activities and $8.6 million for principal payments during the nine months ended September 30, 2024.

Sentiment

Score: 7

Explanation: The document shows a significant positive shift in revenue and profitability due to the commercial launch of HEPZATO. However, the company's liquidity concerns and the need for additional capital raise some concerns, resulting in a moderately positive sentiment.

Positives

• The commercial launch of the HEPZATO Kit in the U.S. has driven significant revenue growth.
• Increased demand for CHEMOSAT in Europe has contributed to overall revenue growth.
• The company achieved net income in the third quarter of 2024, a significant improvement from the previous year.
• The company has sufficient raw material and component parts for the HEPZATO KIT to meet anticipated demand.
• The company has expanded the number of facilities using the HEPZATO KIT to 12 as of October 31, 2024.

Negatives

• The company experienced an operating loss of $1.3 million for the three months ended September 30, 2024, and $15.4 million for the nine months ended September 30, 2024.
• The company reported a net loss of $23.0 million for the nine months ended September 30, 2024.
• The company used $17.7 million in operating activities and $8.6 million for principal payments during the nine months ended September 30, 2024.
• There is uncertainty regarding the company's ability to maintain sufficient liquidity to operate effectively, raising doubts about its ability to continue as a going concern.

Risks

• The company's future results are subject to substantial risks and uncertainties, including the ability to achieve and maintain profitability.
• There is a risk of substantial delays in activating additional sites to administer HEPZATO, which could impact revenue.
• The company may need to raise additional capital through debt or equity offerings, which may not be on favorable terms.
• The company's ability to access existing cash, cash equivalents, and investments may be threatened if additional banks and financial institutions become insolvent.
• The company's future liquidity and capital requirements depend on numerous factors, including the success of commercialization efforts, regulatory approvals, and market developments.

Future Outlook

The company plans to begin one or more studies of the HEPZATO KIT to treat other cancers in the liver in late 2024 or early 2025. The company expects that the publication of additional data from the Phase 3 FOCUS Trial will support increased clinical adoption of and reimbursement for CHEMOSAT in Europe, and support reimbursement in various jurisdictions, including the United States.

Management Comments

• The company intends to manage supply chain risk through stockpiled inventory and contracting with multiple suppliers for critical components.
• The company believes that HEPZATO has the potential to treat other cancers in the liver, such as metastatic colorectal cancer, metastatic neuroendocrine tumors, metastatic breast cancer and intrahepatic cholangiocarcinoma.

Industry Context

The company operates in the interventional oncology space, focusing on liver-directed cancer treatments. The approval and commercial launch of the HEPZATO KIT represents a significant milestone in this field. The company's focus on generating clinical data for CHEMOSAT and HEPZATO, either as monotherapy or in combination with immunotherapy, aligns with the broader industry trend of exploring combination therapies to improve patient outcomes.

Comparison to Industry Standards

• Delcath's revenue growth in Q3 2024, driven by the HEPZATO Kit launch, is a positive sign compared to other companies in the early stages of commercializing novel cancer therapies.
• The reported net income for Q3 2024 is a significant improvement compared to previous quarters and the same period last year, which is a positive indicator compared to other companies in the sector that are still in the development phase.
• The company's cash position of $8.3 million and short-term investments of $5.7 million as of September 30, 2024, is relatively low compared to other companies in the sector with similar market caps, indicating a need for additional capital.
• The company's focus on expanding the use of HEPZATO to other cancers in the liver is consistent with the industry trend of exploring new indications for existing therapies.
• The company's reliance on debt and equity financing is common in the biotech industry, but the uncertainty regarding its ability to maintain sufficient liquidity raises concerns compared to companies with stronger balance sheets.

Legal Proceedings

• The company reached a final settlement with medac GmbH regarding a dispute over a milestone payment, agreeing to pay royalties on sales of CHEMOSAT units or a minimum annual payment.

Stakeholder Impact

• Shareholders may see increased value due to revenue growth and improved profitability.
• Employees may benefit from the company's growth and expansion.
• Customers (hospitals and treatment centers) will have access to the HEPZATO KIT for treating patients with metastatic uveal melanoma.
• Suppliers will benefit from the company's increased demand for raw materials and components.

Next Steps

• The company plans to begin one or more studies of the HEPZATO KIT to treat other cancers in the liver in late 2024 or early 2025.
• The company will continue to focus on commercializing HEPZATO and CHEMOSAT.
• The company will continue to generate clinical data for CHEMOSAT and HEPZATO, either as monotherapy or in combination with immunotherapy.

Key Dates

Keywords

HEPZATO KIT, CHEMOSAT, Uveal Melanoma, Metastatic Liver Cancer, Interventional Oncology, Revenue Growth, Commercial Launch, FDA Approval, Clinical Trials, Medical Device, Pharmaceuticals